about
Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsHairy cell leukemia: Update on molecular profiling and therapeutic advancesThe long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia.Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.Quality Control for RNA-Seq (QuaCRS): An Integrated Quality Control Pipeline.Expression and prognostic impact of lncRNAs in acute myeloid leukemia.Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality.Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.Separating the wheat from the chaff in cHL.Ribosomal revelation.Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenibSelective targeting of NAMPT by KPT-9274 in acute myeloid leukemiaComplex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinicallyImplementation of standardized variant-calling nomenclature in the age of next-generation sequencing: where do we stand?Quantifying Hematopoietic Stem Cell Clonal Diversity by Selecting Informative Amplicon BarcodesTranscriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma ProgressionResistance Mechanisms to SYK Inhibition in Acute Myeloid LeukemiaGenetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid LeukemiaAcalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic LeukemiaClinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years
P50
Q26764833-A6B6FAFA-0437-4D05-BA6A-573919FBF2ACQ26858906-5D99CE60-3178-47D4-B59A-22017A57C940Q33688473-22DE3FE0-DF10-49CD-B259-D91C54E3211BQ34266864-7DD96AB4-D78E-494C-A977-3FCD0E0A6F0DQ34427914-942B5CB2-8B15-48FE-88DA-D3BACF66F8F0Q34831106-B68693A8-EB65-479C-ABF1-DF13B0DE9BE3Q37560138-1C077D49-A82C-48B8-BE1D-145ADB6B3553Q38237619-522D6207-BF6E-4F42-A0AD-B6AF350CB43AQ48226468-F96BEA02-7472-459B-82E9-91089C76385EQ48229128-92A27128-F64E-4919-8108-205F2BC15EC6Q52976044-4D447C4E-28C2-4A90-BDFF-760CD684D17DQ60912335-9CDE8D6E-2540-4F5E-910B-86430A0434DBQ61807712-53071310-B9AC-493D-8176-50D2D4036E25Q64116651-6ED80358-FC5F-4E28-AFE7-EF0B613E2210Q64117802-37275583-8187-4000-B029-DE08F75222AFQ89602635-C332B3DE-0F56-4F31-9BC5-3654555D5816Q91104344-422B9CA8-0DB6-458D-9E12-D66DCB2B7DC0Q91472490-3B805A80-C051-46D6-812C-8C93E1E55D70Q92376072-E76275F3-4996-406A-9D90-8331C5D606CCQ92502482-A8945AEB-A606-49EA-852C-1D876FA691C8Q92965867-7B9077A4-A4A5-4B6B-840A-1C37385BD6E2Q95933763-12405A8C-2DA9-4DEF-971F-1F5847913254
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
James S Blachly
@ast
James S Blachly
@en
James S Blachly
@es
James S Blachly
@nl
James S Blachly
@sl
type
label
James S Blachly
@ast
James S Blachly
@en
James S Blachly
@es
James S Blachly
@nl
James S Blachly
@sl
prefLabel
James S Blachly
@ast
James S Blachly
@en
James S Blachly
@es
James S Blachly
@nl
James S Blachly
@sl
P106
P21
P31
P496
0000-0002-4275-5562